

Eric Nguyen-Khac

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1759639/publications.pdf>

Version: 2024-02-01

71
papers

4,140
citations

236612

25
h-index

114278

63
g-index

80
all docs

80
docs citations

80
times ranked

5863
citing authors

#	ARTICLE	IF	CITATIONS
1	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. <i>JHEP Reports</i> , 2022, 4, 100390.	2.6	15
2	ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts. <i>Liver International</i> , 2022, 42, 1386-1400.	1.9	2
3	Complete endoscopic healing is associated with lower disability than partial endoscopic healing in Crohn's disease: A prospective multicenter study. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101887.	0.7	4
4	Management of alcohol-related liver disease: the French Association for the Study of the Liver and the French Alcohol Society clinical guidelines. <i>Liver International</i> , 2022, 42, 1330-1343.	1.9	10
5	Positive histologic margins is a risk factor of recurrence after ileocaecal resection in Crohn's disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101569.	0.7	5
6	Safety and efficacy of percutaneous transhepatic endoscopic rendezvous procedure in a single session. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 3534-3539.	1.3	2
7	Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. <i>Clinical Therapeutics</i> , 2021, 43, 1201-1212.	1.1	4
8	Impact of cirrhosis aetiology on incidence and prognosis of hepatocellular carcinoma diagnosed during surveillance. <i>JHEP Reports</i> , 2021, 3, 100285.	2.6	4
9	Large-scale screening of lipase acid deficiency in at risk population. <i>Clinica Chimica Acta</i> , 2021, 519, 64-69.	0.5	7
10	Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study. <i>Liver International</i> , 2020, 40, 1042-1051.	1.9	10
11	Type 2 refractory celiac disease on third-generation capsule endoscopy and enteroscopy: typical appearance of ulcerative jejunitis. <i>Endoscopy</i> , 2020, 52, E195-E197.	1.0	1
12	Personalized surveillance for hepatocellular carcinoma in cirrhosis using machine learning adapted to HCV status. <i>Journal of Hepatology</i> , 2020, 73, 1434-1445.	1.8	52
13	Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. <i>Journal of Hepatology</i> , 2020, 73, 1046-1062.	1.8	79
14	Inflammatory bowel disease symptoms at the time of anal fistula lead to the diagnosis of Crohn's disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 968-972.	0.7	6
15	Subclinical proximal tubulopathy in hepatitis B: The roles of nucleotide analogue treatment and the hepatitis B virus. <i>World Journal of Hepatology</i> , 2020, 12, 1326-1340.	0.8	2
16	THU-142-Sofosbuvir + velpatasvir + voxilaprevir in DAA failure patients with cirrhosis: Final results of the French compassionate use program. <i>Journal of Hepatology</i> , 2019, 70, e224.	1.8	4
17	Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II Trial. <i>Radiology</i> , 2019, 291, 801-808.	3.6	31
18	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	3.7	36

#	ARTICLE	IF	CITATIONS
19	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
20	Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis. <i>Digestive and Liver Disease</i> , 2019, 51, 484-488.	0.4	11
21	Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication. <i>Hepatology</i> , 2018, 68, 1245-1259.	3.6	33
22	Benefits of Laparoscopic Approach for Resection of Liver Tumors in Cirrhotic Patients. <i>Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A</i> , 2018, 28, 553-561.	0.5	8
23	Signaling lymphocytic activation molecules Slam and cancers: friends or foes?. <i>Oncotarget</i> , 2018, 9, 16248-16262.	0.8	14
24	The epidemiology of Budd-Chiari syndrome in France. <i>Digestive and Liver Disease</i> , 2018, 50, 931-937.	0.4	32
25	Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. <i>Journal of Hepatology</i> , 2018, 69, 1274-1283.	1.8	86
26	Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 614-625.	3.7	91
27	Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. <i>Kidney International</i> , 2018, 94, 206-213.	2.6	18
28	A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , 2018, 378, 2171-2181.	13.9	383
29	Acute cholangitis complicating a chronic alveolar echinococcosis: an unusual therapeutic cholangioscopy. <i>Endoscopy</i> , 2018, 50, E214-E215.	1.0	0
30	Meckel's diverticulum on third-generation video capsule endoscopy: intradiverticular ulcer, ectopic gastric mucosa, and active bleeding. <i>Endoscopy</i> , 2018, 50, E205-E207.	1.0	4
31	Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. <i>Liver International</i> , 2017, 37, 1314-1324.	1.9	68
32	High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients. <i>Archives of Virology</i> , 2017, 162, 1913-1920.	0.9	2
33	Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology, The</i> , 2017, 18, 1624-1636.	5.1	595
34	DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase. <i>Antiviral Research</i> , 2017, 146, 153-160.	1.9	7
35	Hemoglobin during ribavirin-based HCV therapy is closely related to circulating levels of DHEA. <i>Journal of Medical Virology</i> , 2017, 89, 1033-1039.	2.5	2
36	Incidence, Clinical Presentation, and Associated Factors of Microscopic Colitis in Northern France: A Population-Based Study. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1571-1579.	1.1	48

#	ARTICLE	IF	CITATIONS
37	Cytolytic hepatitis related to simeprevir overdose in a patient with cirrhosis and HIV/HCV genotype 1 coinfection. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 486-487.	0.8	1
38	Management of colorectal cancer in patients with cirrhosis: A retrospective, case-matched study of short- and long-term outcomes. <i>Digestive and Liver Disease</i> , 2016, 48, 429-434.	0.4	16
39	Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 876-881.	0.8	31
40	RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation. <i>Oncotarget</i> , 2016, 7, 9832-9843.	0.8	12
41	Hepatocyte SLAMF3 reduced specifically the multidrugs resistance protein MRP-1 and increases HCC cells sensitization to anti-cancer drugs. <i>Oncotarget</i> , 2016, 7, 32493-32503.	0.8	13
42	Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 517-524.	1.0	6
43	Which therapeutic option for hepatitis C virus genotype 1?. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 470-478.	0.6	3
44	Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. <i>Journal of Hepatology</i> , 2015, 62, 822-830.	1.8	156
45	DHEA and progesterone have a protective effect on ribavirin-induced hemolysis. <i>Journal of Hepatology</i> , 2014, 60, 897-898.	1.8	7
46	Kinetics of relapse after pegylated interferon and ribavirin therapy for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2013, 85, 1191-1198.	2.5	2
47	Human and experimental evidence supporting a role for osteopontin in alcoholic hepatitis. <i>Hepatology</i> , 2013, 58, 1742-1756.	3.6	87
48	Equal efficacy between the two types of peginterferon on HCV: A matter of relapse?. <i>Antiviral Research</i> , 2013, 98, 1-3.	1.9	7
49	The End-of-Treatment Ribavirin Concentration Predicts Hepatitis C Virus Relapse. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 791-795.	1.0	7
50	A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. <i>International Journal of Hepatology</i> , 2013, 2013, 1-11.	0.4	16
51	Is Stenting as a Bridge to Surgery an Oncologically Safe Strategy for the Management of Acute, Left-Sided, Malignant, Colonic Obstruction? A Comparative Study With a Propensity Score Analysis. <i>Annals of Surgery</i> , 2013, 258, 107-115.	2.1	240
52	Identification of SLAMF3 (CD229) as an Inhibitor of Hepatocellular Carcinoma Cell Proliferation and Tumour Progression. <i>PLoS ONE</i> , 2013, 8, e82918.	1.1	13
53	Low incidence of spontaneous bacterial peritonitis in asymptomatic cirrhotic outpatients. <i>World Journal of Hepatology</i> , 2013, 5, 104.	0.8	17
54	The Treatment Response of Chronically Hepatitis C Virus-Infected Patients Depends on Interferon Concentration but Not on Interferon Gene Expression in Peripheral Blood Mononuclear Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 903-908.	1.4	7

#	ARTICLE	IF	CITATIONS
55	A New Tool to Study Ribavirin-Induced Haemolysis. <i>Antiviral Therapy</i> , 2012, 17, 1311-1317.	0.6	10
56	Glucocorticoids plus N-Acetylcysteine in Severe Alcoholic Hepatitis. <i>New England Journal of Medicine</i> , 2011, 365, 1781-1789.	13.9	335
57	Lack of association between tumour necrosis factor receptor types 1 and 2 gene polymorphism and severe acute alcoholic hepatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 794-800.	0.8	4
58	Ribavirin Monitoring in Chronic Hepatitis C Therapy: Anaemia versus Efficacy. <i>Antiviral Therapy</i> , 2010, 15, 687-695.	0.6	56
59	Noninvasive Diagnosis of Large Esophageal Varices by Fibroscan: Strong Influence of the Cirrhosis Etiology. <i>Alcoholism: Clinical and Experimental Research</i> , 2010, 34, 1146-1153.	1.4	45
60	BAD, a Proapoptotic Member of the BCL2 Family, Is a Potential Therapeutic Target in Hepatocellular Carcinoma. <i>Molecular Cancer Research</i> , 2010, 8, 1116-1125.	1.5	50
61	Dynamic measurements of total hepatic blood flow with Phase Contrast MRI. <i>European Journal of Radiology</i> , 2010, 73, 119-124.	1.2	33
62	A Pitfall in the Diagnosis of Unresectable Liver Metastases: Multiple Bile Duct Hamartomas (von Tj ETQq0 0 0 rgBT /Overlock_10 Tf 50 4	0.3	5
63	Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multicenter French study. <i>Cancer Biology and Therapy</i> , 2009, 8, 2033-2039.	1.5	12
64	Optimizing the treatment of chronic viral hepatitis C. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 607-613.	1.4	22
65	The γ 308 TNF α Gene Polymorphism in Severe Acute Alcoholic Hepatitis: Identification of a New Susceptibility Marker. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 822-828.	1.4	14
66	Antioxidants plus corticosteroids in the treatment of severe acute alcoholic hepatitis: The question is still open. <i>Journal of Hepatology</i> , 2008, 49, 147-148.	1.8	2
67	Are ascitic electrolytes usable in cirrhotic patients? Correlation of sodium, potassium, chloride, urea, and creatinine concentrations in ascitic fluid and blood. <i>European Journal of Internal Medicine</i> , 2008, 19, 613-618.	1.0	11
68	Personalized therapy for chronic viral hepatitis C in the naive patient: How can we optimize treatment duration as a function of viral genotype?. <i>European Journal of Internal Medicine</i> , 2007, 18, 510-515.	1.0	4
69	Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. <i>Hepatology</i> , 2007, 46, 1872-1882.	3.6	249
70	Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 1321-1325.	0.8	61
71	Diagnosis of spontaneous bacterial peritonitis in cirrhotic patients by use of two reagent strips. <i>European Journal of Gastroenterology and Hepatology</i> , 2004, 16, 579-583.	0.8	60